Alexey Rak

Head of Bio Structure & Biophysics Sanofi

Alexey Rak got his M.Sc. in Biology and Genetics and in Biochemistry. He then completed Ph.D. in Biochemistry and Biophysics working on protein biosynthesis machinery characterization. He did his post-Doc and then held a Group Leader position at the Max-Planck Institute for Molecular Physiology in Germany working in the field of vesicular membrane trafficking. For this work he was awarded several honors including European Young Investigator Award in 2004. Since 2007 Alexey joined Sanofi in Paris where he has developed new methods to characterize biomolecular interactions as well as new approaches in protein structure determination including cryo-EM and enabling the lead discovery of challenging protein targets. Alexey is heading the center of excellence in Structural Biology and Biophysics in Sanofi and coordinates Structural biology and biophysics Sanofi-wide

Seminars

Wednesday 13th January 2027
Panel Discussion: Expanding the Druggable Universe & the Future of Rational Drug Design in an Era of AI, Structural Biology & Emerging Modalities
9:00 am
  • Explore why complex, dynamic, and previously inaccessible targets have challenged traditional drug discovery approaches
  • Discover how advances in structural biology, biophysics, computational chemistry, and AI are expanding the druggable proteome
  • Understand how molecular glues, degraders, and other emerging modalities reshaping discovery portfolios are and required capabilities
  • Identify which technologies are driving value today versus those likely to transform discovery over the next decade
  • Learn how leading organisations are combining experimental and computational approaches to pursue challenging targets with greater confidence
Wednesday 13th January 2027
Harnessing Generative & Agentic AI to Accelerate Structural Biology & Rational Drug Design
10:00 am
  • Explore the two-way interplay between generative AI and structural biology, leveraging AI to accelerate experimental structure determination while using structural data and metadata to improve predictive models
  • Unlock new opportunities for rational drug design, from de novo biologics and novel small-molecule binding sites to improved target and mechanism-of-action identification
  • Harness agentic AI to transform structural biology workflows, reducing data processing and acquisition times while streamlining sample preparation and increasing experimental productivity
Alexey Rak